- Home
- BRKR vs EXEL Comparison
BRKR vs EXEL Comparison
Compare BRKR & EXEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BRKR
- EXEL
- Stock Information
- Founded
- BRKR 1991
- EXEL 1994
- Country
- BRKR United States
- EXEL United States
- Employees
- BRKR N/A
- EXEL N/A
- Industry
- BRKR Biotechnology: Laboratory Analytical Instruments
- EXEL Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- BRKR Industrials
- EXEL Health Care
- Exchange
- BRKR Nasdaq
- EXEL Nasdaq
- Market Cap
- BRKR 8.4B
- EXEL 9.4B
- IPO Year
- BRKR 2000
- EXEL 2000
- Fundamental
- Price
- BRKR $50.82
- EXEL $36.85
- Analyst Decision
- BRKR Buy
- EXEL Buy
- Analyst Count
- BRKR 13
- EXEL 18
- Target Price
- BRKR $73.27
- EXEL $37.24
- AVG Volume (30 Days)
- BRKR 1.7M
- EXEL 2.6M
- Earning Date
- BRKR 02-13-2025
- EXEL 02-11-2025
- Dividend Yield
- BRKR 0.39%
- EXEL N/A
- EPS Growth
- BRKR N/A
- EXEL 170.77
- EPS
- BRKR 0.76
- EXEL 1.76
- Revenue
- BRKR $3,366,400,000.00
- EXEL $2,168,701,000.00
- Revenue This Year
- BRKR $8.13
- EXEL $5.36
- Revenue Next Year
- BRKR $6.43
- EXEL $10.59
- P/E Ratio
- BRKR $66.95
- EXEL $20.94
- Revenue Growth
- BRKR 13.56
- EXEL 18.49
- 52 Week Low
- BRKR $48.07
- EXEL $20.14
- 52 Week High
- BRKR $94.86
- EXEL $37.59
- Technical
- Relative Strength Index (RSI)
- BRKR 38.94
- EXEL 65.59
- Support Level
- BRKR $49.29
- EXEL $34.01
- Resistance Level
- BRKR $54.48
- EXEL $35.46
- Average True Range (ATR)
- BRKR 2.18
- EXEL 1.09
- MACD
- BRKR -0.21
- EXEL 0.36
- Stochastic Oscillator
- BRKR 23.74
- EXEL 95.70
About BRKR Bruker Corporation
Bruker Corp manufactures scientific instruments and diagnostic tests for customers in the life sciences, pharmaceutical, and biotechnology industries. It operates in four operating segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy and Supercon Technologies (BEST). The company generates maximum revenue from the BSI CALID segment. Geographically, it derives the maximum of its revenue from Asia Pacific.
About EXEL Exelixis Inc.
Exelixis is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its lead molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.